SCHEMBL17199381

SCHEMBL17199381

Cc1ocnc1C(=O)Nc1nn(Cc2ccc(CF)cc2)c2ccccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FSCN1 Q16658 1/20 0.54
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
NCOR2 Q9Y618 1/20 0.42
PTGER4 P35408 8/20 0.41
CNR1 P21554 1/20 0.41
NAMPT P43490 1/20 0.40
GRM1 Q13255 1/20 0.39
F2RL3 Q96RI0 1/20 0.38
SLC16A3 O15427 1/20 0.37
PTGS1 P23219 1/20 0.37
PTGS2 P35354 1/20 0.37
AURKA O14965 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17038846 0.90 FSCN1 (0.69) FSCN1KDM4ENPC1RAB9AHDAC3
SCHEMBL30501124 0.90 FSCN1 (0.69) FSCN1KDM4ENPC1RAB9AHDAC3
SCHEMBL17199316 0.86 FSCN1 (0.54) FSCN1NPC1RAB9AHDAC3HDAC1
SCHEMBL18937505 0.83 FSCN1 (0.57) FSCN1NPC1RAB9AHDAC3HDAC1
SCHEMBL17199315 0.83 FSCN1 (0.55) FSCN1KDM4ENPC1RAB9AHDAC3
SCHEMBL18937456 0.82 FSCN1 (0.49) FSCN1HDAC3HDAC1HDAC2HDAC10
SCHEMBL17199353 0.81 FSCN1 (0.57) FSCN1KDM4ENPC1RAB9AHDAC3
SCHEMBL18937454 0.81 FSCN1 (0.59) FSCN1KDM4EHDAC3HDAC1HDAC2
SCHEMBL18937375 0.80 FSCN1 (0.55) FSCN1KDM4ERAB9AHDAC3HDAC1
SCHEMBL17199347 0.80 FSCN1 (0.60) FSCN1NPC1RAB9AHDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170158692-A1 COMPOUNDS AND METHODS FOR INHIBITING FASCIN CORNELL UNIVERSITY 2017-06-08 US disclosed
US-9573946-B2 Compounds and methods for inhibiting fascin NOVITA PHARMACEUTICALS, INC. (US) 2017-02-21 US disclosed
US-20150299191-A1 COMPOUNDS AND METHODS FOR INHIBITING FASCIN CORNELL UNIVERSITY 2015-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299191-A1 COMPOUNDS AND METHODS FOR INHIBITING FASCIN FSCN1, MTPN, MYOF FSCN1 1/4885KDM4E 4674/4885NPC1 3359/4885
US-20170158692-A1 COMPOUNDS AND METHODS FOR INHIBITING FASCIN FSCN1, MTPN, MYOF FSCN1 1/4885KDM4E 4674/4885NPC1 3359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.